Systematic review: Does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 5, 2009, Pages 459-469

  Andrews, J M ^a   Travis, S P L ^b   Gibson, P R ^c   Gasche, C ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DRUG METABOLITE; IMMUNOMODULATING AGENT; MERCAPTOPURINE; MESALAZINE; OLSALAZINE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER RISK; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; ENTERITIS; HUMAN; LEUKOPENIA; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REOPERATION; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

AMINOSALICYLIC ACIDS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; TREATMENT OUTCOME;

EID: 59149103298     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03915.x     Document Type: Review

References (90)

1. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005 54 : 237 41.
2. Stange EF, Travis SP, Vermeire S, et al. European Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008 2 : 1 23.
3. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl. 1 i16 35.
4. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007 1 : CD000478.
5. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000 2 : CD000067.
6. Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand 1942 110 : 557 90.
7. Baron JH, Connell A, Lennard-Jones J, Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962 3 : 1094 6.
8. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962 29 : 1708 11.
9. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964 5 : 437 42.
10. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 1973 14 : 923 6.
11. Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980 21 : 232 40.
12. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977 2 : 892 5.
13. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993 118 : 540 9.
14. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 5 : 95 102.
15. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 132 : 66 75.
16. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008 57 : 893 902.
17. Kruis W, Gorelov A, Kiudelis G, et al. Once daily dosing of 3 g mesalamaine (Salofalk (R) granules) is therapeutic equivalent to a three-times daily dosing of ig mesalamine for the treatment of active ulcerative colitis. Gastroenterology 2008 132 : A130 1.
18. Dignass A, Vermeire S, Adamek H, et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial [abstract]. Endoscopy 2007 37 : A46 7.
19. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006 23 : 577 85.
20. Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 2005 21 : 1211 6.
21. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003 114 : 39 43.
22. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007 102 : 1417 26.
23. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004 126 : 451 9.
24. Velayos FS, Loftus EV Jr., Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006 130 : 941 9.
25. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005 54 : 1573 8.
26. Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol 2007 23 : 395 9.
27. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004 53 (Suppl. 5 V1 16.
28. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997 92 : 204 11.
29. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 85.
30. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371 : 660 7.
31. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 2 : CD000544.
32. Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004 20 : 143 9.
33. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 2008 27 (Suppl. 1 15 21.
34. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004 126 : 1574 81.
35. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005 1 : CD003715.
36. Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2007 25 : 1389 99.
37. Blomqvist P, Feltelius N, Lofberg R, Ekbom A. A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol Ther 2001 15 : 475 81.
38. Gearry RB, Ajlouni Y, Nandurkar S, Iser JH, Gibson PR. 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis 2007 13 : 1009 15.
39. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004 127 : 730 40.
40. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004 127 : 723 9.
41. Lemann M. Review article: can post-operative recurrence in Crohn's disease be prevented? Aliment Pharmacol Ther 2006 24 (Suppl. 3 22 8.
42. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995 37 : 674 8.
43. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996 91 : 2498 9.
44. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database. Syst Rev 2000 2 : CD000545.
45. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi PG. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006 55 : 47 53.
46. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999 117 : 527 35.
47. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006 101 : 1274 82.
48. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001 13 : 1297 301.
49. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004 99 : 1122 8.
50. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002 16 : 79 85.
51. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995 39 : 456 9.
52. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006 12 : 251 7.
53. Gilissen LP, Derijks LJ, Verhoeven HM, et al. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig Liver Dis 2007 39 : 182 6.
54. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997 62 : 464 75.
55. Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005 22 : 605 11.
56. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004 26 : 311 8.
57. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006 24 : 715 29.
58. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999 116 : 1505 6.
59. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001 49 : 656 64.
60. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006 51 : 2165 9.
61. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 23 : 1296 310.
62. Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925 170 : 220 7.
63. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut 1994 35 : 651 5.
64. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994 35 : 1590 2.
65. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001 48 : 526 35.
66. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992 103 : 1444 51.
67. Jess T, Loftus EV Jr., Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006 130 : 1039 46.
68. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004 2 : 1088 95.
69. Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006 12 : 205 11.
70. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006 130 : 1030 8.
71. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990 323 : 1228 33.
72. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988 29 : 206 17.
73. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006 23 : 1097 104.
74. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995 22 : 1404 8.
75. Jess T, Loftus EV Jr., Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007 102 : 829 36.
76. Velayos FS, Loftus EV Jr., Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006 130 : 1941 9.
77. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003 98 : 2784 8.
78. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005 100 : 1345 53.
79. Boland CR, Luciani MG, Gasche C, Goel A. Infection, inflammation, and gastrointestinal cancer. Gut 2005 54 : 1321 31.
80. Strevel EL, Irvine EJSF, Steinhart AH. Immunosuppressives and surgery reduce risk of GI cancers in patients with Crohn's disease: a case control study. Can J Gastroenterol 2005 19 (Suppl. B 5B.
81. Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 2005 65 : 3993 7.
82. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007 132 : 221 35.
83. Goel A, Nagasaka T, Gasche C, Boland CR. Chemopreventive effects of mesalazine through inhibition of DNA methyltransferases and reactivation of methylation-silenced genes in human colon cancer cells. Gastroenterology 2007 1 : A39.
84. Joshi R, Kumar S, Unnikrishnan M, Mukherjee T. Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free Radic Res 2005 39 : 1163 72.
85. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 2006 27 : 2371 82.
86. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005 201 : 1205 15.
87. Schwab M, Reynders V, Loitsch S, et al. PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 2008 29 : 1407 14.
88. Monteleone G, Franchi L, Fina D, et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 2006 13 : 202 11.
89. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003 24 : 443 51.
90. Stolfi C, Fina D, Caruso R, et al. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis 2008 29 : 1258 66.